Compare Twist Bioscience Corp (TWST) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Materials Select Sector SPDR Fund — how do they compare? Twist Bioscience Corp trades at $159 (market cap $10.08B), while Materials Select Sector SPDR Fund trades at $49.33 (market cap $7.73B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| TWST | XLB | |
|---|---|---|
Market Cap | $10.08B | $7.73B |
Volume | 4,229,037 | 13,681,146 |
Sector | Health | — |
52-Week High | $205.00 | $53.67 |
52-Week Low | $25.45 | $42.23 |
Typical Hold Time | 27 Days | 70 Days |
Enterprise Value | $10.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
XLB, the Materials Select Sector SPDR ETF, trades at $48.98, down 1.51% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The ETF's portfolio is heavily concentrated in chemicals (49% of assets), and recent news highlights sector volatility amid broader market challenges outside of tech. A dividend of $0.23 is scheduled for September 2026, but financial ratios are currently unavailable.
The outlook for XLB is cautious due to technical weakness and sector cyclicality, though long-term infrastructure and AI-related demand offer potential upside. Risks include economic sensitivity and high concentration, while investor sentiment remains mixed with some analysts seeing value in materials as an AI-resistant play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
